Friday 6 November 2026 Export HAE’s income statement to Excel — free account

Haemonetics Corporation

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.

Revenue: +9.30%
EPS: +25.9%
Free cash flow: +20.4%
Total debt: +21.0%

Quarter to September 2026, against a year earlier

119.97 4.14 −3.34%

Follow HAE

Alert me

Market cap: $5.7B
P/E: 54.5×
Fwd P/E: 30.2×
Dividend yield: —
F-score: 6/9
Altman Z: 2.21
Beneish M: −2.81
Dividend safety: n/a

Overview

Haemonetics Corporation (HAE) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Haemonetics Corporation (HAE) trades at a P/S ratio of 4.1×. Over the past ten years it has ranged from 1.5× (May 2016) to 8.0× (February 2021); the current reading is higher than 73% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/HAE/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Haemonetics Corporation P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/HAE/metrics/ps-ratio">Haemonetics Corporation (HAE) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2026	2.0×	(15.20%)
FY2025	2.4×	(28.44%)
FY2024	3.3×	(8.66%)
FY2023	3.6×	10.66%
FY2022	3.2×	(49.73%)
FY2021	6.5×	26.48%
FY2020	5.1×	6.92%
FY2019	4.8×	13.50%
FY2018	4.2×	78.52%
FY2017	2.4×	20.39%

Period	P/S ratio	Change
Sep 2026	3.5×	37.73%
Jun 2026	2.5×	26.24%
Mar 2026	2.0×	(29.94%)
Dec 2025	2.8×	62.86%
43 more quarters	Free account

Against its own ten years

Low 1.5× High 8.0×

Ten-year median 3.3×

Current reading's percentile 71

Company	P/S ratio
ITGR Integer Holdings Corporation compare	2.4×
BRKR Bruker Corporation compare	2.5×
LIVN LivaNova PLC compare	3.4×
BIO Bio-Rad Laboratories, Inc. compare	3.8×
BIO.B Bio-Rad Laboratories, Inc. compare	3.9×
HAE Haemonetics Corporation	4.1×
IRTC iRhythm Holdings, Inc. compare	5.1×
AXGN AxoGen, Inc. compare	10.1×
TXG 10x Genomics compare	12.4×
Medical Devices industry median	2.5×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Haemonetics Corporation (HAE) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on HAE

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on HAE

Stockrow Weekly